Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Preferred Stock Liabilities (2021 - 2022)

Prime Medicine's Preferred Stock Liabilities history spans 2 years, with the latest figure at $395.8 million for Q3 2022.

  • For Q3 2022, Preferred Stock Liabilities rose 101.78% year-over-year to $395.8 million; the TTM value through Sep 2022 reached $395.8 million, up 101.78%, while the annual FY2021 figure was $395.8 million, N/A changed from the prior year.
  • Preferred Stock Liabilities reached $395.8 million in Q3 2022 per PRME's latest filing, up from $199.6 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $395.8 million in Q4 2021 to a low of $196.2 million in Q3 2021.